The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan

por Jhund, Pardeep S, McMurray, John J V
Publicado 2016

Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction

por Packer, Milton, McMurray, John J.V.
Publicado 2021

Binding Modes of Peptidomimetics Designed to Inhibit STAT3

por Dhanik, Ankur, McMurray, John S., Kavraki, Lydia E.
Publicado 2012

DINC: A new AutoDock-based protocol for docking large ligands

por Dhanik, Ankur, McMurray, John S, Kavraki, Lydia E
Publicado 2013

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure

por Docherty, Kieran F., McMurray, John J.V.
Publicado 2020

Insights into foundational therapies for heart failure with reduced ejection fraction

por McMurray, John J. V., Docherty, Kieran F.
Publicado 2022

Hydrodehalogenation of Alkyl Iodides with Base-Mediated Hydrogenation and Catalytic Transfer Hydrogenation: Application to the Asymmetric Synthesis of N-Protected α-Methylamines

por Mandal, Pijus K., Birtwistle, J. Sanderson, McMurray, John S.
Publicado 2014

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?

por Kondo, Toru, Jhund, Pardeep S., McMurray, John J.V.
Publicado 2022

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure

por Cannon, Jane A, McMurray, John JV, Quinn, Terry J
Publicado 2015

Who Benefits From a Defibrillator—Balancing the Risk of Sudden Versus Non-sudden Death

por Beggs, Simon A. S., Gardner, Roy S., McMurray, John J. V.
Publicado 2018

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction

por Dewan, Pooja, Docherty, Kieran F., McMurray, John J.V.
Publicado 2019

Talking to patients with heart failure about end of life

por Campbell, Ross T., Petrie, Mark C., McMurray, John J.V.
Publicado 2018

The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the...

por McMurray, John S., Mandal, Pijus K., Liao, Warren S., Klostergaard, Jim, Robertson, Fredika M.
Publicado 2012

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context

por McMurray, John J V, Solomon, Scott D, Docherty, Kieran F, Jhund, Pardeep S
Publicado 2020

What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?

por Cannon, Jane A, McKean, Andrew R, Jhund, Pardeep S, McMurray, John J V
Publicado 2015

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

por Sattar, Naveed, McLaren, James, Kristensen, Søren L., Preiss, David, McMurray, John J.
Publicado 2016

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

por Sattar, Naveed, McLaren, James, Kristensen, Søren L., Preiss, David, McMurray, John J.
Publicado 2016

Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it

por Ahmad, Faheem A., Petrie, Mark C., McMurray, John J.V., Lang, Ninian N.
Publicado 2019

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

por Lee, Matthew M. Y., Sattar, Naveed, McMurray, John J. V., Packard, Chris J.
Publicado 2019

Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma

por Sarkar, Aloke, Balakrishnan, Kumudha, Chen, Jefferson, Patel, Viralkumar, Neelapu, Sattva S., McMurray, John S., Gandhi, Varsha
Publicado 2015